A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A ...

After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI ...

In an interview with Stephen Onikoro, chief operating officer of PharmaForceIQ, he shared that pharma marketers can’t pour ...

Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly ...

A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in ...

Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.

For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that ...

Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the ...

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.

The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an ...

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically ...